Public Funding for Copner Biotech Ltd

High precision inkjet bioprinting has the potential to improve critical biomedical research, whilst replacing/reducing reliance on animal testing. Currently, the precision of bioprinting platforms for the research sector is limited and incapable of recreating complex architectures visualised _in vivo_ efficiently, with batch-to-batch consistency, for a tissue of interest, This project will see the development of a novel inkjet bioprinting system with a bespoke software operating system, as well as a next generation inkjet collagen Type 0 bioink formulation derived from jellyfish offering the ability to recreate complex 3D architecture and optimal in vivo efficacy.